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REVIEW

Use of clopidogrel in the reduction of myocardial
damage during percutaneous coronary intervention
Arijit Dasgupta
Debabrata Mukherjee
Gill Heart Institute, University
of Kentucky, Lexington, KY, USA

Abstract: It is estimated that approximately a quarter of patients undergoing coronary intervention
may have signiﬁcant post-procedural creatinine (CK)/creatinine kinase myocardial band (CK-MB)
elevations and approximately half may have post-procedural troponin elevations. Current data suggest that periprocedural infarction is associated with short-, intermediate-, and long-term adverse
outcomes, most notably mortality. This review examines the role of clopidogrel in decreasing
periprocedural myonecrosis following percutaneous coronary intervention (PCI). Clopidogrel is
an important pharmacologic agent used to reduce myocardial infarction post-coronary intervention
as assessed directly by the evaluation of cardiac biomarkers and indirectly by the evaluation of
short-term ischemic events. The optimal dose of clopidogrel is considered to be at least 300 mg
given 6 to 15 hours prior to PCI but there is considerable evidence to suggest that a loading dose
of 600 mg given 2 to 6 hours prior to PCI may be more efﬁcacious in limiting post-coronary intervention events. The beneﬁt obtained from clopidogrel appears independent of and incremental to
that of other antiplatelet and antithrombotic agents used during and after coronary intervention.
Keywords: percutaneous coronary intervention, myonecrosis, clopidogrel, antiplatelet agents,
myocardial infarction
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Percutaneous coronary intervention (PCI) has become the most common form of
coronary revascularization in the United States with greater than 900,000 procedures
performed annually.1 Although overall a safe procedure, PCI does have multiple associated risks including bleeding, coronary dissection, and abrupt vessel closure. These
complications are obviously undesirable and intuitively associated with negative longterm outcomes but an even more frequent and important contributor to the mortality
and morbidity associated with PCI is periprocedural myonecrosis and infarction.2 The
deﬁnition of periprocedural myocardial infarction was standardized in 2007 with a
post-procedure elevation of cardiac biomarkers more than 3 times the 99th percentile
upper reference limit (URL) deﬁned as PCI-related myocardial infarction (MI).3 It is
estimated that approximately 25% of patients undergoing PCI have signiﬁcant postprocedural creatinine (CK)/creatinine kinase myocardial band (CK-MB) elevations and
approximately 50% of patients have signiﬁcant post-procedural troponin elevations.2
Initially, it was felt these elevations were simple enzyme leaks with no long-term
implications. Multiple data sets have now deﬁnitively demonstrated that periprocedural
infarction is associated with short-, intermediate-, and long-term adverse outcomes,
most notably mortality.4–7 This review examines the role of clopidogrel in decreasing
periprocedural myonecrosis following PCI.

Pathophysiology of periprocedural myonecrosis
and the role of clopidogrel therapy
PCI invariably results in mechanical plaque disruption with some degree of associated endothelial injury. Platelet attachment then occurs at the site of endothelial
Vascular Health and Risk Management 2009:5 275–286
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injury through platelet surface interactions with the exposed
extracellular matrix (ECM) and exposed von Willebrand
Factor (vWF).8 Following platelet attachment, a series of
platelet activating steps occur including the secretion of various secondary messengers including ADP, thromboxane A2,
and serotonin.9 These messengers result in further autoactivation of platelets and subsequent platelet morphological
changes resulting in ﬁrm platelet adhesion, activation of
thrombin, and eventual full platelet aggregation via the
glycoprotein IIb/IIIa integrin receptor.10 Local vasoconstriction and inﬂammation, combined with the accumulation and
embolization of platelet aggregates, results in thrombosis,
ischemia, and infarction in the microvascular circulation.11
Endogenous release of vasodilators such as adenosine is
able to compensate to some degree but when sufﬁcient
platelets aggregate, they are able to exceed all compensatory
mechanisms and the result is periprocedural myonecrosis
and/or infarction. This highlights the importance of platelet-dependent processes in the pathophysiology of ischemic
complications following PCI.
This importance of platelet activity in post-PCI ischemic
complications was clinically demonstrated by the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial, Full
Anticoagulation Versus Ticlopidine plus Aspirin after Stent
Implantation (FANTASTIC) trial, and Stent Anticoagulation
Regimen Study (STARS) trials.12–14 Each trial demonstrated
the superiority of an anti-platelet approach (aspirin and/or
ticlopidine) over anticoagulation in the reduction of the composite endpoint of cardiovascular (CV) death, MI, or need
for recurrent revascularization following stent placement and
speciﬁc post-procedural outcomes such as early stent thrombosis. These trials helped established the role of anti-platelet
therapy in reducing both periprocedural and post discharge
ischemic complications following PCI.
Three key classes of anti-platelet agents are used currently
in clinical practice: aspirin, intravenous glycoprotein IIb/IIIa
inhibitors, and thienopyridines. The thienopyridine class of
antiplatelet agents is composed of ticlopidine, clopidogrel,
and prasugrel which is under FDA review. These drugs
act through non-competitive, irreversible antagonism of
the ADP binding site on the P2Y12 receptor on platelets.15
Ticlopidine’s use was limited by its twice-daily formulation
and by the main side effects of occasional neutropenia, and
even more rarely thrombotic thrombocytopenia purpura
(TTP).15 Clopidogrel is a second generation thienopyridine
agent with an oral formulation requiring gastrointestinal
absorption mediated by the P-glycoprotein efﬂux pump
followed by a 2 step cytochrome p-450 dependent activation
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resulting in the active metabolite.16 The use of clopidogrel
in place of ticlopidine began in 2000, after the Clopidogrel
Aspirin Stent International Cooperative Study (CLASSICS)
trial demonstrated better tolerability proﬁle with no change
in the rates of recurrent ischemic events.17

Clopidogrel and present data
In the current era, clopidogrel’s important pharmacotherapeutic role has been expanded to include patients undergoing PCI for any indication including non-ST elevation acute
coronary syndrome (NSTE ACS), routine elective PCI, and
ST elevation myocardial infarction (STEMI). The evidence
for this comes from three main trials: Effects of Pretreatment with Clopidogrel and Aspirin Followed by Long-Term
Therapy in Patients Undergoing Percutaneous Coronary
Intervention: the PCI-CURE Study (PCI-CURE), Early
and Sustained Dual Oral Antiplatelet Therapy Following
Percutaneous Coronary Intervention: A Randomized Control Trial (CREDO), and Effect of Clopidogrel Pretreatment
Before Percutaneous Coronary Intervention in Patients wit
ST-Elevation Myocardial Infarction Treated with Fibrinolytics: the PCI-CLARITY Study (PCI-CLARITY).18–20
These trials demonstrated the clear and consistent beneﬁt
of clopidogrel, speciﬁcally clopidogrel pretreatment, in
the prevention of ischemic complications post-PCI. These
trials also helped clarify the optimal timing of clopidogrel
pretreatment in limiting thrombotic and ischemic complications post PCI.
PCI-CURE aimed to investigate whether pretreatment
followed by long term administration of clopidogrel with PCI
was superior to no clopidogrel pretreatment and short-term
clopidogrel therapy in terms of reducing post-PCI ischemic
events. The study examined outcomes in 2658 patients with
NSTE-ACS enrolled in the original Clopidogrel in Unstable
Angina to prevent Recurrent Events (CURE) trial21 who
underwent angiography and PCI at the discretion of the
treating physician. These patients had been randomized at
presentation to clopidogrel (N = 1313) or placebo (N = 1345)
with a 300 mg loading dose followed by 75 mg daily per
CURE trial protocol. Patients received pretreatment with
clopidogrel for a mean of 6 days prior to angiography.
Following PCI, ⬎80% of patients in both groups received
open-label thienopyridine for 4 weeks, after which the study
drug (placebo versus clopidogrel) was restarted for a mean
of 8 months.
The primary endpoint was a composite of CV death,
MI, or urgent target-vessel revascularization (TVR) within
30 days of PCI. Although the study did not directly assess for
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periprocedural MI rates through routine screening for
post-procedure increases in cardiac enzymes, the results did
suggest a marked decrease in this outcome. The study found
a signiﬁcant decrease in the primary composite endpoint
in the clopidogrel group versus the placebo group (4.5%
versus 6.4%; p = 0.03). This difference was driven mostly
by a decrease in the number of MIs (2.1% versus 3.8%) and
speciﬁcally q-wave MIs (0.8% versus 2.4%) post PCI. CV
death and urgent TVR rates were statistically similar between
the two groups. This lower rate of the primary endpoint was
seen as early as 2 days after PCI implicating a reduction in
periprocedural MI and the beneﬁt continued until 30 days
(Figure 1). As both groups of patients received clopidogrel
post PCI for at least 30 days at equally high rates, the beneﬁt
of the marked reduction in periprocedural MI was likely due
to the effects of clopidogrel pre-treatment with a 300 mg load
followed by a 75 mg daily dose given a mean of 6 days prior
to PCI. Thus although this study ﬁrst highlighted the importance of clopidogrel loading prior to PCI to help decrease
PCI-related myonecrosis, the optimal timing of this loading
dose was not yet clear.
The CREDO study 1 9 randomized 1815 patients
undergoing planned PCI to 300 mg clopidogrel loading
at presentation (N = 900) versus placebo loading at presentation (N = 915) with subsequent clopidogrel daily in
both groups through day 28. Following this, the clopidogrel loading group continued on clopidogrel from day 29

through 12 months while the placebo group was restarted
on placebo. Both groups had routine evaluation for periprocedural MI deﬁned as an elevation in the CK or CK-MB
levels to at least 3 times the upper limit of normal (ULN)
in 2 samples collected at different sampling times. At
28 days, the composite endpoint of death, MI, and urgent
TVR was assessed in both groups. The mean duration
between clopidogrel loading and PCI was 9.8 hours but
with 51% of patients receiving their load less than 6 hours
before PCI.
Clopidogrel loading was associated with a non-signiﬁcant
decrease in the composite endpoint at 28 days (6.8% pretreatment versus 8.3% no pretreatment, p = 0.23, Figure 2).
For each individual component of the combined end point,
there were fewer events in patients receiving clopidogrel
pretreatment. When the groups were re-analyzed based on
the prespeciﬁed loading time intervals of 3 to 6 hours, 6 to
12 hours, and 12 to 24 hours prior to PCI, an important
interaction was noted between the timing of pretreatment
and reduction in the composite endpoint. Patients receiving
clopidogrel between 3 and 6 hours prior to PCI had no
beneﬁt compared to placebo whereas patients treated 6 to
12 and 12 to 24 hours before PCI had progressively increased
protection from adverse cardiac events at 28 days. Patients
who received a 300 mg clopidogrel loading at least 6 hours
before PCI experienced a 38.6% relative reduction in the
composite endpoint at 8 days that was of borderline statistical
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Figure 1 Kaplan Meier cumulative event rates for primary endpoint at 30 days after PCI in the PCI CURE study. Reprinted from The Lancet, 358, Mehta SR,Yusuf S, Peters RJ,
et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study,
527–533,18 Copyright © 2001, with permission from Elsevier.
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Figure 2 CREDO combined end points at 28 Days. Reproduced with permission from Steinhubl et al. JAMA. 2002;288(19):2411–2420.19 Copyright © 2005 American Medical
Association. All rights reserved.

signiﬁcance (p = 0.051, Figure 2). In a subsequent analysis of
these data, the CREDO investigators found that the benef it of
clopidogrel loading became highly signiﬁcant when administered at least 15 hours prior the procedure.22 Thus CREDO
expanded the indication for clopidogrel therapy to a more
stable ischemic population group and also suggested the
optimal clopidogrel therapy prior to PCI in terms of reduction
of periprocedural thrombotic events was a loading dose of
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300 mg given at least 6 hours and optimally 15 hours prior
to PCI followed by a maintenance daily dose.
PCI-CLARITY20 examined the outcomes of 1863 patients
with STEMI who per study protocol had received ﬁbrinolytic
therapy followed by routine angiography and then underwent
PCI at the discretion of the treating physician. These patients
had been randomly assigned to clopidogrel (N = 933) or
placebo (N = 930) prior to angiography. Patients randomized
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to clopidogrel received a 300 mg loading dose followed by
75 mg per day with the load being given within 45 minutes of
the start of ﬁbrinolytic therapy. The primary efﬁcacy outcome
was a composite of CV death, recurrent MI, or stroke from
the time of PCI to 30 days after randomization. CK-MB was
measured 3 times over 24 hours following intervention to
ensure systematic monitoring for post-PCI MI which was
deﬁned as CK-MB of at least 3 times ULN and if CK-MB
was already elevated, a CK-MB increase by 50% over the
previous value. The median number of days of clopidogrel
administration prior to PCI was 3 days.
Pretreatment with clopidogrel signiﬁcantly reduced the
rate of CV death, MI, or stroke following PCI through 30 days
after randomization (3.6% versus 6.2%, p = 0.008). The
beneﬁt of pretreatment was directionally consistent among
all the components of the composite end point. Event curves
revealed the two treatment groups separated soon after PCI
and continued to diverge over time (Figure 3). Even though
the median duration of time between randomization and PCI
was 3 days, the benef it of pretreatment seemed consistent
across the broad range of pretreatment durations ranging
from 6 hours to 8 days.
Taken together, the PCI-CURE, CREDO, and PCICLARITY studies demonstrated a consistent beneﬁt with
clopidogrel pretreatment in terms of reduction of shortterm cardiac events following PCI (Figure 4). As CREDO
and PCI-CLARITY speciﬁcally examined and included

periprocedural MI in their short term composite primary
endpoint analysis, the use of clopidogrel certainly suggests
a reduction in this event while analysis of PCI-CURE suggested a decrease in short-term events driven speciﬁcally by
a decrease in periprocedural MIs.
The benef it of clopidogrel in PCI in terms of reduction
of myocardial necrosis is demonstrated in reduced short term
cardiac events but also can be inferred from the higher rates
of TIMI 3 f low seen in patients who receive clopidogrel pretreatment. In PCI-CLARITY, a higher percentage of patients
receiving clopidogrel versus placebo had TIMI 3 ﬂow at the
time of their protocol mandated angiography.20 A meta-analysis
of 38 trials comparing patients with STEMI treated with PCI
receiving clopidogrel pretreatment versus placebo found similar results with a highly signiﬁcant increase in TIMI 3 f low in
patients pretreated with clopidogrel (OR 1.53, p ⬍ 0.0001).23
This meta-analysis also conﬁrmed the signiﬁcant decrease in
short term (⬍42 days) mortality and death/reinfarction seen
PCI-CURE, CREDO, and PCI-CLARITY when patients were
pretreated with clopidogrel (Figure 5).
These studies demonstrate the importance of clopidogrel
pretreatment in terms of reducing periprocedural myonecrosis
and associated short term cardiac events and is the basis
for the current American College of Cardiology (ACC)/
American Heart Association (AHA) class 1 recommendation for the use of clopidogrel pretreatment with a 300 mg
loading dose given at least 6 hours before PCI in patients
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Figure 3 Outcomes at 30 days in the PCI-CLARITY study. Reproduced with permission from Sabatine et al. JAMA. 2005;294(10):1224–1232.20 Copyright © 2005 American
Medical Association. All rights reserved.
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Source

Clopidogrel

Placebo

OR (95% CI)

PCI-CURE

38/1313 (2.9)

59/1345 (4.4)

0.65 (0.43–0.98)

CREDO

54/9000 (6.0)

65/915 (7.1)

0.83 (0.57–1.21)

PCI-CLARITY

31/933 (3.3)

50/930 (5.4)

0.60 (0.38–0.96)

Overall

123/3146 (3.9)

174/3 190 (5.5)

0.71 (0.56–0.89)
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P = 0.004
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Figure 4 Summary of PCI studies assessing the effect of clopidogrel treatment. Reproduced with permission from Sabatine et al. JAMA. 2005;294(10):1224–1232. Copyright ©
2005 American Medical Association. All rights reserved.
20

with acute coronary syndrome as well as in those undergoing
elective intervention.24

Optimal pre-treatment dose: higher
loading dose and chronic therapy
Observational data demonstrated that a 600 mg loading dose
of clopidogrel caused an earlier and stronger inhibition of
adenosine diphosphate (ADP)-induced platelet activation
than a 300 mg loading dose.25,26 Based on these studies, the
Antiplatelet Therapy for Reduction of Myocardial Damage
during Angioplasty (ARMYDA-2) study was carried out to
test the hypothesis of whether a higher loading dose of 600 mg
clopidogrel would reduce post-PCI events compared to a
standard 300 mg dose in patients undergoing elective PCI.27
A total of 329 patients scheduled for PCI were randomized
to a 600 mg (N = 163) or 300 mg (N = 166) loading regimen
of clopidogrel given 4 to 8 hours (mean of 6 hours) before
the procedure. The primary endpoint of the study was 30-day
occurrence of death, MI, or TVR. CK-MB, troponin I, and
myoglobin levels were measured at baseline and at 8 and
24 hours after PCI and the secondary end points included any
post-procedural increase of these markers above the ULN.

The primary endpoint occurred in 4% of patients in the
high loading dose versus 12% in the standard loading group
(p = 0.041). This reduction in the primary endpoint was driven
entirely by a decrease in rates of periprocedural MI; 15 MI
occurred in the 300 mg group versus 5 in the 600 mg group.
Peak values of all cardiac biomarkers were signiﬁcantly lower
in patients treated with the 600 mg regimen (Figure 6).
The ARMYDA-2 study suggested patients given a
600 mg loading dose of clopidogrel 6 hours prior to PCI
experienced fewer periprocedural MI than those receiving a 300 mg loading dose. The majority of patients in
both arms of the ARMYDA-2 study were low risk stable
angina patients (75% in both high and conventional loading dose arms). When the higher loading 600 mg dose was
tested exclusively in higher risk patients with NSTE-ACS,
similar superior outcomes at 1 month post-PCI was noted
in the high-risk patients given 600 mg loading dose versus
conventional 300 mg dose; a 1-month follow up period
revealed recurrent cardiovascular events occurring at 5%
and 12% respectively (p = 0.02).28 A meta-analysis conducted by Lotrionte et al29 further investigated the beneﬁt
of high dose clopidogrel loading versus standard 300 mg

Unadjusted treatment effect
OR

95% CI

P

TIMI grade 2/3 flow

1.53

1.39–1.68

<0.0001

Mortality

0.52

0.41–0.67

<0.0001

Death/reinfarction

0.50

0.40–0.62

<0.0001

Figure 5 Meta-analysis of clopidogrel pretreatment in STEMI patients undergoing PCI with respect to short-term outcomes. Reproduced with permission from Vlaar PJ,
Svilaas T, Damman K, et al. Impact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for
ST-segment elevation myocardial infarction: a systematic review. Circulation. 2008;118(18):1828–1836.23 Copyright © 2008 Lippincott Williams and Wilkins.
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Figure 6 Peri-procedural biomarker changes in the ARMYDA-2 study. Reproduced with permission from Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading
dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for
Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111(16):2099–2106.27 Copyright © 2005 Lippincott Williams and Wilkins.

loading in patients undergoing PCI. The meta-analysis
included 10 trials (7 randomized and 3 non-randomized)
with a total of 1567 patients enrolled. Overall, a high loading
dose (⬎300 mg) proved signiﬁcantly superior to a standard
loading dose in terms of reducing early cardiac death or
non-fatal MI post PCI (odds ratio 0.54, p = 0.02). This
analysis also found that patients at highest risk, deﬁned by
the presence of elevated cardiac biomarkers, beneﬁted the
most with the increased loading dose.
Although these studies suggest the beneﬁcial role for a
600 mg clopidogrel loading dose versus the 300 mg loading
dose, the optimal timing of the higher dose is somewhat
controversial. In the ARMYDA-2 trial, the 600 mg loading
dose was given between 4–8 hours with a mean of 6 hours
prior to PCI suggesting the optimal timing is 6 hours prior
to intervention. Platelet functional studies have shown that
the 600 mg dose of clopidogrel achieves maximal platelet
inhibition 2 hours after administration.30 This has led to the
overall consensus that the 600 mg loading dose should be
given at least 2 hours, and optimally 6 hours, prior to PCI.
The Intracoronary Stenting and Antithrombotic Regimen:
Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect (ISAR-CHOICE) trial investigated whether
loading doses higher than 600 mg of clopidogrel exerted
additional suppression of platelet function.31 The study
compared the effects of 300, 600, and 900 mg clopidogrel
doses on platelet function among stable patients scheduled
for coronary angiography. Sixty patients were assigned to
1 of 3 clopidogrel loading schemes in a randomized, double
blinded manner. Optical aggregometry was performed
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before and 4 hours after administration of clopidogrel. At
4 hours, patients treated with both 600 and 900 mg doses
demonstrated greater inhibition of platelet aggregation (IPA)
than the 300 mg dose. No signiﬁcant difference in platelet
inhibition was found between the 600 and 900 mg doses. On
the basis of this ﬁnding, the ISAR-CHOICE trial concluded
that single clopidogrel loading dosages ⬎600 mg was not
associated with any additional suppression of platelet activity. The trial also found, through the measured levels of clopidogrel metabolites in the differing loading dose schemes,
that the maximal clopidogrel loading dose of 600 mg was
perhaps related to impaired intestinal absorption beyond the
600 mg dose.31
The Assessment of the Best Loading Dose of Clopidogrel
to Blunt Platelet Activation, Inﬂammation, and Ongoing
Necrosis (ALBION) trial, in contrast to ISAR-CHOICE
found that there was greater platelet inhibition with 900 mg
loading dose of clopidogrel compared to 600 mg loading
dose in reference to the 300 mg baseline loading dose.32
The ALBION study assessed platelet aggregation through
standard ADP induced optical aggregometry in 35 patients
randomized to 300 mg, 34 patients randomized to 600 mg,
and 34 patients randomized to 900 mg clopidogrel. Platelet
aggregometry was measured 8 times in the ﬁrst 6 hours and
the study found increased inhibition of platelet activity (IPA)
at higher loading dosage compared to standard dose with near
equal time to maximal effect at 5 to 6 hours. It should be
noted that no direct comparison of degree of platelet inhibition was made between the 600 mg and 900 mg doses. The
trial was too small to assess clinical outcomes but did suggest
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that increased loading dosages may be useful in higher risk
patients as there was increased platelet inhibition.
A related question of clopidogrel dosing involves whether
patients who are already receiving a maintenance dose of
clopidogrel should receive a booster load. The ARMYDA-4
study examined the efﬁcacy of a reloading dose of clopidogrel in patients with stable angina or NSTE-ACS undergoing
PCI who were on chronic clopidogrel therapy.33 Investigators
followed patients randomly assigned to a reload arm
(N = 180) with a 600 mg clopidogrel load given 4 to 8 hours
prior to PCI versus patients randomly assigned to a placebo
arm (N = 180). The primary endpoint was a composite of
death, MI, and TVR at 30 days. The secondary endpoints
included increase in post-procedure biomarkers, peak values
of myocardial enzymes, point of care evaluation of platelet
activity, and bleeding complications. The composite primary
endpoint was identical in the reload and placebo arms (8%
versus 7%). The primary endpoint was driven exclusively
by MI as there were no deaths and no TVR. Myocardial
markers, platelet aggregometry, and bleeding complications
were also identical in both arms. This study concluded that
patients on chronic clopidogrel did not require reloading
prior to PCI.
The main limitations of the ARMYDA-4 study included
its small size and the fact that the majority of the enrolled
patients were relatively stable with less than one third of the
patients presenting with ACS. Subsequently, the ARMYDARELOAD study examined a higher risk population of patients
taking chronic clopidogrel therapy.33 The study followed
436 patients on chronic clopidogrel therapy (at least 10 days)
of which 167 patients had presented with ACS and examined the effect of reloading with 600 mg clopidogrel versus
placebo on post-PCI outcomes. The primary endpoint was a
composite endpoint of death, MI, and TVR at 30 days. Platelet
reactivity was also measured in both groups. Overall, there
was again no demonstrable difference in the primary endpoint
between the 2 groups (7% clopidogrel reload arm versus 9%
in placebo arm, p = 0.7) but when the ACS subgroup was analyzed alone, there was a signiﬁcant reduction in the primary
endpoint in the reload arm (7% versus 18%, p = 0.035).
Platelet reactivity was also signiﬁcantly lower in the ACS
subgroup receiving a 600 mg reload. Thus although this study
was essentially negative, it did suggest the beneﬁcial role of
a 600 mg reload given 4 to 8 hours prior to PCI in patients
on chronic clopidogrel therapy presenting with ACS.
In the Dose Effect of Clopidogrel Reloading in Patients
Already on 75 mg Maintenance Dose: the Reload With Clopidogrel Before Angioplasty in Subjects Treated Long Term
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With Dual Antiplatelet Therapy (RELOAD) Study, Collet et al
examined whether patients on chronic clopidogrel beneﬁted
from a 900 mg reload dose.34 The dosage scheme of reloading
was given in 3 different strategies allowing further examination of the hypothesis raised by ISAR-CHOICE that there was
a maximal absorption threshold of 600 mg which limited the
beneﬁt of higher load dosing schemes. The study’s primary
endpoint was inhibition of platelet activity as measured by optical aggregometry. Clinical endpoints of death, MI, and TVR
were also measured at 30 days. The study found that clopidogrel reloading with 900 mg did have signiﬁcant increase in
platelet inhibition compared to lower loading doses and there
was no evidence of an absorption threshold which limited the
beneﬁt of the 900 mg loading dose. There was no difference in
the clinical endpoint between any of the dosing schemes. Thus
although the study provided evidence for the use of a 900 mg
loading dose in terms of platelet reactivity, the lack of clinical
beneﬁt made the ﬁndings difﬁcult to interpret.
Overall, all of the above studies have suggested that a
clopidogrel loading dose of 600 mg or 900 mg may be more
beneﬁcial than a 300 mg loading dose in terms of reducing postPCI events. As most of these trials had small sample sizes, ACC/
AHA guidelines still ofﬁcially considers clopidogrel 300 mg as
an adequate loading dose but it does note that higher loading
dose can be considered prior to PCI.24 The ongoing Clopidogrel
Optimal Loading Dose Usage to Reduce Recurrent Events/
Optimal Antiplatelet Strategy for Interventions (OASIS-7)
trial will randomize 14,000 high risk NSTE-ACS patients to
300 mg versus 600 mg loading clopidogrel dose prior to PCI and
should help further clarify the beneﬁt of higher loading doses
in terms of short-term (⬍30 days) post-PCI events.35

Personalized therapy
Much of the impetus for the higher dosing of clopidogrel is
due to the wide variability of clopidogrel associated platelet
inhibition, ie, the presence of clopidogrel resistance and its
clinical implications. Hochholzer et al showed that in patients
undergoing elective PCI who were pre-loaded with 600 mg
clopidogrel, the degree of platelet inhibition as measured
by ADP-induced optical aggregometry prior to intervention
predicted the likelihood of post-PCI myocardial events.36
Patients within the lower third and fourth quartile of platelet
inhibition were at a signiﬁcantly higher risk of worse shortterm outcomes compared to those in the higher quartiles of
platelet inhibition (Figure 7). This ﬁnding was also seen in
the Antiplatelet Therapy for the Reduction of Myocardial
Damage during Angioplasty – Platelet Reactivity Predicts
Outcomes (ARMYDA-PRO) study which also assessed
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Figure 7 Degree of platelet inhibition and major cardiovascular events. Reproduced with permission from Hochholzer W,Trenk D, Bestehorn HP, et al. Impact of the degree of
peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006;48(9):1742–1750.36
Copyright © 2006 Elsevier.

platelet activity after a 600 mg loading clopidogrel dose but
used a rapid cartridge based assay (VerifyNow P2Y12 Assay)
rather than optical aggregometry.37
These studies led to the hypothesis that tailored therapy
to overcome clopidogrel resistance could result in improved
post-PCI outcomes. Although ADP-induced optical
aggregometry is considered the gold standard in terms of
assessing platelet function in patients receiving clopidogrel,
it is a difﬁcult test to perform at the bedside therefore its use
in tailored therapy is limited.38 Additionally, ADP-induced
optical aggregometry is somewhat non-speciﬁc as the effects
of ADP on the P2Y1 receptor are included in this test but
clopidogrel action does not involve this receptor. Schwarz
et al found that the activity of clopidogrel and ticlopidine
with its associated blockade of the P2Y12 receptor could be
monitored through analysis of the intracellular vasodilatorstimulated phosphoprotein (VASP) phosphorylation state.39
Barragan et al used ﬂow cytometry to quantitate the VASP
phosphorylation state and developed the VASP index which
is essentially a ratio of platelet activity that is inversely related
to the effect of clopidogrel.40 This study also found that a
VASP index greater than 50% was associated with a higher
risk of subacute stent thrombosis.
Bonello et al prospectively examined the use of the tailored clopidogrel dosing using the VASP index on post-PCI
outcomes.41 This study initially measured the VASP index
24 hours after a 600 mg clopidogrel loading dose in patients
undergoing planned PCI for refractory angina, silent ischemia
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on stress testing, and NSTEMI. Patients with a VASP
index ⬎50% were ofﬁcially enrolled in the study (N = 162)
and were randomized to a control group (N = 84) versus
further VASP-guided clopidogrel dosing (N = 78). In the
control group, PCI was carried out without additional clopidogrel. In the VASP-guided group, patients were given up to
3 additional 600 mg clopidogrel doses in 24-hour increments
until the VASP index was below 50%. The effect of each
additional clopidogrel dose is shown in Figure 8. One-month
follow-up demonstrated a signiﬁcant improvement in clinical
outcomes with the control group having an overall major
adverse cardiovascular event (MACE) rate of 10% including
1 case of acute stent thrombosis and 3 cases of subacute stent
thrombosis versus 0% in the VASP guided group (p = 0.007,
Figure 9). This study provided clinical evidence for tailored
clopidogrel therapy based on platelet activity but is limited
by its small sample size. The ongoing Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis
And Safety (GRAVITAS) trial will compare outcomes in
6600 patients randomized to tailored therapy using platelet
functional testing versus standard therapy and should help
clarify whether there is real beneﬁt to this approach.

Benefit of clopidogrel
and adjunctive therapies
All studies demonstrating the beneﬁt of clopidogrel in terms
of reducing post-PCI myocardial necrosis have been against
the background of aspirin use so dual antiplatelet therapy is
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Figure 8 Effect of additional clopidogrel dosing on VASP Index. Reproduced with permission from Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses
according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:
a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51(14):1404–1411.41 Copyright © 2008 Elsevier.

mandatory for optimal beneﬁt. Additionally antithrombotic
use with heparin or enoxaparin was also routine in all studies demonstrating the beneﬁts of clopidogrel in the setting
of PCI. A meta-analysis by Sabatine et al42 examined the
PCI-CURE, CREDO, and PCI-CLARITY trials and demonstrated that there was added beneﬁt to pretreatment with
clopidogrel regardless of the use glycoprotein IIB/IIIA
inhibitors (GP IIB/IIIA inhibitors). This suggested that
patients undergoing PCI who were started on GP IIB/IIIA
inhibitors still beneﬁted from the presence of clopidogrel
loading in terms of reducing post-PCI events provided the
dose was given adequately before the actual time of PCI. The
Intracoronary Stenting and Anti-thrombotic Regimen: Rapid
End point

Early Action for Coronary Treatment (ISAR-REACT) trial
demonstrated that in low risk patients, there is in fact no beneﬁt, in terms of short term clinical post-PCI events, to adding
GP IIB/IIIA inhibitors if clopidogrel loading with 600 mg is
administered at least 2 hours prior to PCI. Thus in low risk
patients, clopidogrel loading with 600 mg seems to provide
adequate platelet activity inhibition with no need for further
anti-platelet therapy.43 In contrast higher risks patients, as
deﬁned by the presence of positive troponins, do seem to
have additional beneﬁt in terms of reduced post-PCI events
when a GP IIB/IIIA inhibitor is used in addition to clopidogrel pretreatment. This was demonstrated by the ISARREACT 2 trial which enrolled 2022 patients presenting with
Control group
n (%)

VASP-Guided group

n (%)

Cardiovascular death

2 (2)

0

Acute stent thrombosis

1 (1)

0

Subacute stent thrombosis

3 (4)

0

Recurrent acute coronary
syndrome

2 (2)

0

All MACE

8 (10)

0

Figure 9 One month clinical outcomes standard versus VASP-guided clopidogrel loading. Reproduced with permission from Bonello L, Camoin-Jau L, Arques S, et al. Adjusted
clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with
clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol. 2008;51(14):1404–1411.41 Copyright © 2008 Elsevier.
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NSTE-ACS undergoing PCI after being loaded with 600 mg
clopidogrel at least 2 hours prior to intervention.44 Patients
were administered abciximab (N = 1012) versus placebo
(N = 1010) in a double-blinded, randomized manner at the
time of PCI. A composite of ischemic events (death, MI,
urgent TVR) was assessed 30 days post PCI and found to be
signiﬁcantly reduced in the abciximab group versus placebo
(8.9% versus 11.9%, p = 0.03). This beneﬁt was limited only
to patients with an elevated troponin. The ACUITY trial
demonstrated that the use of the direct thrombin inhibitor
bivalirudin was not inferior to the use of GP IIB/IIIA inhibitor and enoxaparin or unfractionated heparin (UFH) in the
management of patients presenting with NSTE-ACS with
respect to 30-day rates of a composite endpoint of death,
MI, or urgent TVR.45 Clopidogrel therapy was not mandated
by protocol in either arm but a loading dose of 300 mg no
later than 2 hours post-PCI and daily maintenance therapy
of 75 mg was recommended. There was no signiﬁcant difference in the proportion of patients receiving clopidogrel
therapy in the bivalirudin versus GP IIB/IIIA plus enoxaparin or UFH arms (64.2% versus 62.3% respectively).
Subgroup analysis of this study suggested that patients on
bivalirudin monotherapy who did not receive clopidogrel
prior to PCI had increased ischemic events post-procedure
compared to patients receiving GP IIB/IIIA and enoxaparin
or UFH (9.1% versus 7.1%; 95% CI 1.03 to 1.63). This suggested that use of bivalirudin in patients with NSTE-ACS
requiring PCI should be limited to patients who have been
pre-treated with clopidogrel. A subsequent post-hoc analysis
by Lincoff et al46 found that as long as clopidogrel is administered before or within 30 minutes post-PCI, treatment with
bivalirudin is equivalent (non-inferior) to enoxaparin or UFH
and GP IIB/IIIA inhibitor in terms of short-term post-PCI
ischemic outcomes.

Conclusion
Clopidogrel is an important pharmacologic agent used to
reduce MI post-PCI as assessed directly by the evaluation
of cardiac biomarkers post-intervention and indirectly by
the evaluation of short term ischemic events. The optimal
dose of clopidogrel is considered to be at least 300 mg given
at least 6 to 15 hours prior to PCI but there is considerable
evidence to suggest a loading dose of 600 mg given 2 to
6 hours prior to PCI may be more efﬁcacious in limiting
post-PCI events. Doses higher than 600 mg may be still
more efﬁcacious especially in patients with evidence of
clopidogrel resistance as assessed by platelet function testing but this is controversial and requires further randomized
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testing to verify. The beneﬁt of clopidogrel therapy in the
reduction of post-PCI ischemic events is independent and
complementary to other adjunctive therapies including aspirin, UFH/enoxaparin, GP IIB/IIIA, and bivalirudin.
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